THYROCARE.NS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 10:19):

Stats
Šios dienos apimtis	10 502.00
Vidutinė apimtis	115 686
Rinkos kapitalizacija	34.47B
EPS	INR0 ( 2024-02-01 )
Kita pelno data	( INR0 ) 2024-05-21
Last Dividend	INR18.00 ( 2023-04-20 )
Next Dividend	INR0 ( N/A )
P/E	53.14
ATR14	INR0.329 (0.05%)

Tūris Koreliacija

Ilgas: 0.00 (neutral)

Trumpas: 0.84 (strong)

Signal:(42.457) Same movement expected

Thyrocare Technologies Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Thyrocare Technologies Koreliacija - Valiuta/Žaliavos

-0.24
( neutral )

-0.36
( neutral )

0.00
( neutral )

-0.05
( neutral )

0.20
( neutral )

-0.07
( neutral )

Thyrocare Technologies Finansinės ataskaitos

Annual	2022
Pajamos:	INR5.27B
Bruto pelnas:	INR3.63B (69.01 %)
EPS:	INR12.16

FY	2022
Pajamos:	INR5.27B
Bruto pelnas:	INR3.63B (69.01 %)
EPS:	INR12.16

FY	2022
Pajamos:	INR5.89B
Bruto pelnas:	INR4.19B (71.18 %)
EPS:	INR33.30

FY	2021
Pajamos:	INR4.95B
Bruto pelnas:	INR3.31B (66.86 %)
EPS:	INR21.41

Financial Reports:

No articles found.

Thyrocare Technologies Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR18.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Thyrocare Technologies Dividend Information - Dividend Junior

Dividend Sustainability Score: 2.68 - low (50.00%) | Divividend Growth Potential Score: 5.08 - Potential for dividend initiation, but uncertain (1.67%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR2.50	2016-09-01
Last Dividend	INR18.00	2023-04-20
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	11	--
Total Paid Out	INR105.50	--
Avg. Dividend % Per Year	1.39%	--
Score	2.33	--
Div. Sustainability Score	2.68
Div.Growth Potential Score	5.08
Div. Directional Score	3.88	--

Next Divdend (Est)
(2024-06-24)

INR19.97 Estimate 3.36 %

Dividend Stability

0.27 Very Poor

Dividend Score

2.33

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR10.00	1.55%
2019	INR25.00	4.64%
2020	INR10.00	1.85%
2021	INR15.00	1.60%
2022	INR15.00	1.35%
2023	INR18.00	2.94%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SARDAEN.NS	Dividend Junior	2023-09-07	Annually	15	0.65%
MAGADSUGAR.NS	Dividend Junior	2023-07-13	Annually	7	1.78%
GMDCLTD.NS	Dividend Knight	2023-09-22	Annually	23	3.41%
ASTRAMICRO.NS	Dividend Junior	2023-08-23	Annually	20	0.49%
TITAN.NS	Dividend Junior	2023-07-13	Annually	20	0.35%
PETRONET.NS	Dividend Knight	2023-08-18	Semi-Annually	18	2.36%
JASH.NS	Dividend Junior	2023-09-22	Annually	7	0.57%
DBOL.NS	Dividend Junior	2023-06-23	Insufficient data to determine frequency	2	0.56%
SILINV.NS	Dividend Junior	2023-08-18	Annually	23	0.63%
MBAPL.NS	Dividend Junior	2023-09-18	Annually	8	0.44%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.118	1.500	7.63	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.128	1.500	9.69	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	24.85	1.000	1.909	1.909	[3 - 30]
operatingCashFlowPerShareTTM	16.82	2.00	4.39	8.79	[0 - 30]
freeCashFlowPerShareTTM	16.82	2.00	1.590	3.18	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.708	1.000	1.541	1.541	[0.2 - 0.8]
operatingProfitMarginTTM	0.168	1.000	8.63	8.63	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				2.68

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	52.64	1.000	4.78	0	[1 - 100]
returnOnEquityTTM	0.128	2.50	9.80	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	16.82	2.00	4.39	3.18	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	16.82	2.00	4.39	8.79	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.948	1.500	7.01	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.161	1.000	8.48	0	[0.1 - 0.5]
Total Score				5.08

Thyrocare Technologies

Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates in three segments: Diagnostic Testing Services, Imaging Services, and Others. The company conducts various medical diagnostic tests and profiles of tests that focuses on early detection and management of disorders and diseases, including thyroid, growth, metabolism, auto-immunity, diabetes, anaemia, cardiovascular, infertility, COVID, and various infectious diseases. Its profiles of tests include 34 profiles of tests administered under its Aarogyam brand, which offers patients a suite of wellness and preventive health care tests. The company also sells glucometer and glucostrips under the brand name Sugarscan; consumables; and radiopharmaceutical. Thyrocare Technologies Limited was founded in 1996 and is based in Navi Mumbai, India. Thyrocare Technologies Limited is a subsidiary of Docon Technologies Private Limited.